55.9003  0.55 (0.99%)		10-28 11:51
Open: 55 High: 56.165 Volume: 429,455		Pre. Close: 55.35 Low: 54.885 Market Cap: 10,821(M)

Short term
Mid term
Targets	6-month :	70.24	1-year :	74.75
Resists	First :	60.14	Second :	64
Pivot price	55.36
Supports	First :	53.9	Second :	44.84
MAs	MA(5) :	55.77	MA(20) :	55.99
	MA(100) :	60.5	MA(250) :	57.8
MACD	MACD :	-1.6	Signal :	-1.9
%K %D	K(14,3) :	44.8	D(3) :	45.8
RSI	RSI(14): 39.7
52-week	High :	70.98	Low :	49.25

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ BMRN ] has closed above bottom band by 49.3%. Bollinger Bands are 61.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	56.84 - 57.19	57.19 - 57.44
Low:	54.49 - 54.94	54.94 - 55.25
Close:	55.17 - 55.82	55.82 - 56.27

BioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The company currently markets several key pharmaceutical products. Among these are Vimizim, an enzyme replacement therapy targeting mucopolysaccharidosis (MPS) IV type A, a specific lysosomal storage disorder, and Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for individuals with MPS VI. Another notable offering is Kuvan, a unique synthetic oral version of 6R-BH4, prescribed for phenylketonuria (PKU), an inherited metabolic condition. Further expanding its product portfolio, BioMarin provides Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme administered via subcutaneous injection to lower blood Phe levels. Also available are Brineura, a recombinant human tripeptidyl peptidase 1 used in treating ceroid lipofuscinosis type 2, a variant of Batten disease; Voxzogo, a daily injectable c-type natriuretic peptide analog for achondroplasia; and Aldurazyme, a refined protein mirroring the naturally occurring human enzyme alpha-L-iduronidase. Beyond its established products, BioMarin has a robust development pipeline. This includes valoctocogene roxaparvovec, an adeno-associated virus vector undergoing Phase III clinical trials for severe hemophilia A. Additionally, BMN 307, an AAV5-mediated gene therapy, is in Phase 1/2 trials, aiming to normalize blood phenylalanine levels in PKU patients, while BMN 255 is also in Phase 1/2 trials for primary hyperoxaluria. Its clientele spans specialty pharmacies, hospitals, international government health bodies, and a network of distributors and pharmaceutical wholesalers. These services reach patients and healthcare providers across the United States, Europe, Latin America, and other global markets. BioMarin maintains strategic licensing and collaborative alliances with partners such as Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. Established in 1996, the company's corporate headquarters are located in San Rafael, California.

Tue, 27 Oct 2026
BioMarin Pharmaceutical (BMRN) Could Be 24% Undervalued Ahead Of Its November 2 Results Call - Simply Wall Street

Mon, 26 Oct 2026
BioMarin Pharmaceutical Inc. (BMRN) stock price, news, quote and history - Yahoo Finance UK

Mon, 26 Oct 2026
BioMarin Pharmaceutical (BMRN): Amicus Acquisition Accelerates Revenue Growth - AlphaStreet

Mon, 26 Oct 2026
BioMarin to Host Third Quarter 2026 Financial Results Conference Call and Webcast on Monday, November 2, 2026, at 4:30pm ET - TradingView

Mon, 26 Oct 2026
A third-quarter results call will include a business update from BioMarin’s CEO on Nov. 2. - Stock Titan

Sun, 25 Oct 2026
BioMarin Pharmaceutical Inc. (BMRN) Stock Forecasts - Yahoo! Finance Canada

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	194 (M)
Shares Float	193 (M)
Held by Insiders	0.3 (%)
Held by Institutions	103.2 (%)
Shares Short	11,520 (K)
Shares Short P.Month	9,880 (K)

EPS	0.37
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	32.65
Profit Margin	2.1 %
Operating Margin	21.1 %
Return on Assets (ttm)	3.2 %
Return on Equity (ttm)	1.1 %
Qtrly Rev. Growth	19.8 %
Gross Profit (p.s.)	8.98
Sales Per Share	17.61
EBITDA (p.s.)	3.33
Qtrly Earnings Growth	-81.4 %
Operating Cash Flow	857 (M)
Levered Free Cash Flow	85 (M)

PE Ratio	149.59
PEG Ratio	0.3
Price to Book value	1.69
Price to Sales	3.14
Price to Cash Flow	12.5

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.